Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Martin Cannon

TitleProfessor
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentMicrobiology & Immunology, College of Medicine
DivisionMicrobiology & Immunology Faculty
Address521C Biomedical Research I
325 S. Elm St.
Mail Slot # 511
Little Rock AR 72205
Phone501-296-1254
vCardDownload vCard
    Other Positions
    TitleAssociate Professor
    InstitutionUniversity of Arkansas for Medical Sciences
    DepartmentObstetrics And Gynecology, College of Medicine


    Collapse Research 
    Collapse research activities and funding
    HT94252411008     (CANNON, MARTIN)Nov 15, 2024 - Nov 14, 2027
    US Department of Defense
    Mechanisms of Combinatorial Therapy to Enhance Anti-PD-1 Immune Checkpoint Inhibition for Ovarian Cancer
    Role: Principal Investigator
    R21CA288928     (CANNON, MARTIN J)Mar 7, 2024 - Feb 28, 2026
    NIH
    Mechanisms of Th17-DC immunotherapy for ovarian cancer
    Role: Principal Investigator
    R21CA288928     (CANNON, MARTIN)Mar 7, 2024 - Feb 28, 2026
    NIH/Nat. Cancer Institute
    Mechanisms of Th17-DC immunotherapy for ovarian cancer
    Role: Principal Investigator
    U01AI170039     (PATHAK, RUPAK)Jul 25, 2022 - May 31, 2027
    NIH
    Platelets in radiation-induced immune dysregulation
    Role: Co-Principal Investigator
    5R01CA245083     (CANNON, MARTIN)Sep 15, 2021 - Aug 31, 2026
    NIH/Nat. Cancer Institute - Pass Through: NIH/Nat. Cancer Institute
    Improvement of cellular immunotherapy during dysbiosis
    Role: Principal Investigator
    R01CA245083     (DINGS, RUUD P.M.)Sep 15, 2021 - Aug 31, 2026
    NIH
    Improvement of cellular immunotherapy during dysbiosis- Resubmission
    Role: Co-Investigator
    80NSSC21M0323     (PATHAK, RUPAK)Aug 15, 2021 - Aug 14, 2025
    National Aeronautics & Space Administration - Pass Through: Arkansas Space Grant Consortium
    Preventing immune system dysregulation during deep-space missions by Tocofexol, a modified isomer of vitamin E - AA request
    Role: Principal Investigator
    W81XWH2110460     (CANNON, MARTIN)Jul 1, 2021 - Dec 31, 2024
    US Department of Defense
    Proteogenomic analysis of responders versus nonresponders in a Phase I clinical trial of Th17-inducing dendritic cell vaccination for advanced stage ovarian cancer
    Role: Principal Investigator
    813467     (CANNON, MARTIN)Jan 1, 2021 - Dec 31, 2024
    Ovarian Cancer Research Fund Alliance
    Understanding and targeting myeloid populations in ovarian cancer for enhancing therapeutic effects
    Role: Principal Investigator
    W81XWH2010642     (CANNON, MARTIN)Aug 1, 2020 - Jul 31, 2023
    Congressionally Directed Medical Research Programs
    Enhancement of Th17-Inducing DC Vaccination for Ovarian Cancer Through PARPi-Mediated Activation of Innate Immunity in the Tumor Microenvironment
    Role: Principal Investigator
    P50CA13693     (CANNON, MARTIN)Sep 1, 2019 - Aug 31, 2020
    NIH/Nat. Cancer Institute - Pass Through: Mayo Clinic
    Mayo Clinic Ovarian Cancer SPORE - Pilot Project
    Role: Principal Investigator
    R01CA236209     (TACKETT, ALAN)Jun 15, 2019 - May 31, 2024
    NIH
    Identification of Druggable Targets to Complement Melanoma Therapy
    Role: Co-Investigator
    F31CA232464     (KOSS, BRIAN)Mar 1, 2019 - Feb 28, 2022
    NIH
    Epigenetic regulation of metabolic stress pathways in melanoma infiltrating lymphocytes- Resubmission
    Role: Co-Investigator
    R01CA214511     (FRANCO, AIME T)Jul 3, 2018 - Aug 31, 2024
    NIH
    MAPK pathway modulation in thyroid tumorigenesis
    Role: Co-Investigator
    W81XWH-17-1-0142     (CANNON, MARTIN)Jul 1, 2017 - Jun 30, 2020
    US Department of Defense
    CD206-targeted alleviation of immune suppression by ovarian tumor-associated macrophages
    Role: Principal Investigator
    P50CA136393     (CANNON, MARTIN)Sep 11, 2015 - Aug 31, 2020
    NIH/Nat. Cancer Institute - Pass Through: Mayo Clinic
    Th17-inducing vaccine strategies for preventing progression of ovarian cancer
    Role: Principal Investigator
    009     (CANNON, MARTIN)Jul 1, 2011 - Jun 30, 2013
    The Mary Kay Foundation
    Dendritic cell activation of therapeutic Th17 responses against ovarian cancer
    Role: Principal Investigator
    009-11     (CANNON, MARTIN)Jul 1, 2011 - Jun 30, 2013
    The Mary Kay Foundation
    Dendritic cell activation of therapeutic Th17 responses against ovarian cancer
    Role: Principal Investigator
    W81XWH-08-1-0281     (CANNON, MARTIN)Aug 1, 2008 - Aug 31, 2010
    US Department of the Army
    Dendritic cell vaccination and immune regulation in ovarian cancer
    Role: Principal Investigator
    R41CA108257     (CANNON, MARTIN J)May 1, 2005 - Apr 30, 2007
    NIH
    Dendritic cell immunotherapy for ovarian cancer
    Role: Principal Investigator
    R01CA098927     (CANNON, MARTIN J)Aug 9, 2004 - May 31, 2009
    NIH
    Novel target antigens for ovarian cancer immunotherapy
    Role: Principal Investigator
    DAMD17     (ZHAROV, VLADIMIR)Jul 15, 2003 - Aug 14, 2004
    Cubist Pharmaceuticals, Inc.
    NanoPhotothermolysis of Breast Tumors: Feasibility with Photothermal Imaging
    Role: Principal Investigator
    DAMD17-00-1-0589     (CANNON, MARTIN)Sep 15, 2000 - Sep 14, 2004
    US Department of the Army
    CD 8+ Cytotoxic T Cell Responses to Novel Ovarian Cancer Antigens (immunotherapy, ovarian cancer, gynecologic oncology, cytotoxic T lymphocytes, dendr
    Role: Principal Investigator
    R29CA063931     (CANNON, MARTIN J)May 1, 1994 - Feb 29, 2000
    NIH
    T-CELL IMMUNOTHERAPY OF EBV ASSOCIATED LYMPHOMA
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions. Don't see publications published under other names? Login to add alternative names.
    List All   |   Timeline
    1. Ferdous KU, Tesfay MZ, Cios A, Shelton RS, Hartupee C, Urbaniak A, Chamcheu JC, Mavros MN, Giorgakis E, Mustafa B, Simoes CC, Miousse IR, Basnakian AG, Moaven O, Post SR, Cannon MJ, Kelly T, Nagalo BM. Enhancing Neoadjuvant Virotherapy's Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer. Biomedicines. 2024 Jul 18; 12(7). PMID: 39062169.
      View in: PubMed
    2. Luo Y, Shreeder B, Jenkins JW, Shi H, Lamichhane P, Zhou K, Bahr DA, Kurian S, Jones KA, Daum JI, Dutta N, Necela BM, Cannon MJ, Block MS, Knutson KL. Th17-inducing dendritic cell vaccines stimulate effective CD4 T cell-dependent antitumor immunity in ovarian cancer that overcomes resistance to immune checkpoint blockade. J Immunother Cancer. 2023 11; 11(11). PMID: 37918918.
      View in: PubMed
    3. Zhang Y, Gabere M, Taylor MA, Simoes CC, Dumbauld C, Barro O, Tesfay MZ, Graham AL, Ferdous KU, Savenka AV, Chamcheu JC, Washam CL, Alkam D, Gies A, Byrum SD, Conti M, Post SR, Kelly T, Borad MJ, Cannon MJ, Basnakian A, Nagalo BM. Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy. Front Oncol. 2022; 12:1042250. PMID: 36457491.
      View in: PubMed
    4. Conrad SJ, Raza T, Peterson EA, Liem J, Connor R, Nounamo B, Cannon M, Liu J. Myxoma virus lacking the host range determinant M062 stimulates cGAS-dependent type 1 interferon response and unique transcriptomic changes in human monocytes/macrophages. PLoS Pathog. 2022 09; 18(9):e1010316. PMID: 36103568.
      View in: PubMed
    5. Block MS, Dietz AB, Gustafson MP, Kalli KR, Erskine CL, Youssef B, Vijay GV, Allred JB, Pavelko KD, Strausbauch MA, Lin Y, Grudem ME, Jatoi A, Klampe CM, Wahner-Hendrickson AE, Weroha SJ, Glaser GE, Kumar A, Langstraat CL, Solseth ML, Deeds MC, Knutson KL, Cannon MJ. Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients. Nat Commun. 2020 10 14; 11(1):5173. PMID: 33057068.
      View in: PubMed
    6. Jenkins SV, Robeson MS, Griffin RJ, Quick CM, Siegel ER, Cannon MJ, Vang KB, Dings RPM. Gastrointestinal Tract Dysbiosis Enhances Distal Tumor Progression through Suppression of Leukocyte Trafficking. Cancer Res. 2019 12 01; 79(23):5999-6009. PMID: 31591154.
      View in: PubMed
    7. Cannon MJ, Block MS, Morehead LC, Knutson KL. The evolving clinical landscape for dendritic cell vaccines and cancer immunotherapy. Immunotherapy. 2019 02; 11(2):75-79. PMID: 30730268.
      View in: PubMed
    8. Morehead LC, Cannon MJ. Further clinical advancement of dendritic cell vaccination against ovarian cancer. Ann Res Hosp. 2018 Aug; 2. PMID: 30345421.
      View in: PubMed
    9. Ou Y, Cannon MJ, Nakagawa M. Regulatory T Cells in Gynecologic Cancer. MOJ Immunol. 2018; 6(2):34-42. PMID: 30637330.
      View in: PubMed
    10. Lamichhane P, Karyampudi L, Shreeder B, Krempski J, Bahr D, Daum J, Kalli KR, Goode EL, Block MS, Cannon MJ, Knutson KL. IL10 Release upon PD-1 Blockade Sustains Immunosuppression in Ovarian Cancer. Cancer Res. 2017 12 01; 77(23):6667-6678. PMID: 28993412.
      View in: PubMed
    11. Allam H, Johnson BP, Zhang M, Lu Z, Cannon MJ, Abbott KL. The glycosyltransferase GnT-III activates Notch signaling and drives stem cell expansion to promote the growth and invasion of ovarian cancer. J Biol Chem. 2017 09 29; 292(39):16351-16359. PMID: 28842505.
      View in: PubMed
    12. Nounamo B, Liem J, Cannon M, Liu J. Myxoma Virus Optimizes Cisplatin for the Treatment of Ovarian Cancer In?Vitro and in a Syngeneic Murine Dissemination Model. Mol Ther Oncolytics. 2017 Sep 15; 6:90-99. PMID: 28875159.
      View in: PubMed
    13. Cannon MJ, Ghosh D, Gujja S. Signaling Circuits and Regulation of Immune Suppression by Ovarian Tumor-Associated Macrophages. Vaccines (Basel). 2015 May 29; 3(2):448-66. PMID: 26343197.
      View in: PubMed
    14. Kieber-Emmons T, Pennisi A, Lane A, Siegel E, Cannon M, Monzavi-Karbassi B, Makhoul I. Defining and managing expectations for early immunotherapy cancer trials. Rev Recent Clin Trials. 2015; 10(1):47-60. PMID: 25723736.
      View in: PubMed
    15. Mirandola L, Yu Y, Cannon MJ, Jenkins MR, Rahman RL, Nguyen DD, Grizzi F, Cobos E, Figueroa JA, Chiriva-Internati M. Galectin-3 inhibition suppresses drug resistance, motility, invasion and angiogenic potential in ovarian cancer. Gynecol Oncol. 2014 Dec; 135(3):573-9. PMID: 25284038.
      View in: PubMed
    16. Goyne HE, Stone PJ, Burnett AF, Cannon MJ. Ovarian tumor ascites CD14+ cells suppress dendritic cell-activated CD4+ T-cell responses through IL-10 secretion and indoleamine 2,3-dioxygenase. J Immunother. 2014 Apr; 37(3):163-9. PMID: 24598451.
      View in: PubMed
    17. Goyne HE, Cannon MJ. Dendritic cell vaccination, immune regulation, and clinical outcomes in ovarian cancer. Front Immunol. 2013 Nov 18; 4:382. PMID: 24302925.
      View in: PubMed
    18. Cannon MJ, Goyne HE, Stone PJ, Macdonald LJ, James LE, Cobos E, Chiriva-Internati M. Modulation of p38 MAPK signaling enhances dendritic cell activation of human CD4+ Th17 responses to ovarian tumor antigen. Cancer Immunol Immunother. 2013 May; 62(5):839-49. PMID: 23354626.
      View in: PubMed
    19. Goyne HE, Cannon MJ. The case for HER2/neu as a therapeutic target for gynecologic malignancies. Immunotherapy. 2012 Aug; 4(8):781-4. PMID: 22947006.
      View in: PubMed
    20. Kim KH, Greenfield WW, Cannon MJ, Coleman HN, Spencer HJ, Nakagawa M. CD4+ T-cell response against human papillomavirus type 16 E6 protein is associated with a favorable clinical trend. Cancer Immunol Immunother. 2012 Jan; 61(1):63-70. PMID: 21842207.
      View in: PubMed
    21. Chiriva-Internati M, Mirandola L, Yu Y, Jenkins MR, Gornati R, Bernardini G, Gioia M, Chiaramonte R, Cannon MJ, Kast WM, Cobos E. Cancer testis antigen, ropporin, is a potential target for multiple myeloma immunotherapy. J Immunother. 2011 Jul-Aug; 34(6):490-9. PMID: 21654522.
      View in: PubMed
    22. Goyne H, Stone PJ, Cannon MJ. Combinatorial strategies for alleviation of tumor-associated immune suppression and therapeutic vaccination against ovarian cancer. Immunotherapy. 2011 Jul; 3(7):805-7. PMID: 21751946.
      View in: PubMed
    23. Chiriva-Internati M, Yu Y, Mirandola L, D'Cunha N, Hardwicke F, Cannon MJ, Cobos E, Kast WM. Identification of AKAP-4 as a new cancer/testis antigen for detection and immunotherapy of prostate cancer. Prostate. 2012 Jan; 72(1):12-23. PMID: 21520158.
      View in: PubMed
    24. Chiriva-Internati M, Mirandola L, Kast WM, Jenkins MR, Cobos E, Cannon MJ. Understanding the cross-talk between ovarian tumors and immune cells: mechanisms for effective immunotherapies. Int Rev Immunol. 2011 Apr-Jun; 30(2-3):71-86. PMID: 21557635.
      View in: PubMed
    25. Chiriva-Internati M, Cobos E, Cannon MJ. Prospects and challenges for immunotherapy of ovarian cancer--what can we learn from the tumor microenvironment? Int Rev Immunol. 2011 Apr-Jun; 30(2-3):67-70. PMID: 21557634.
      View in: PubMed
    26. Cannon MJ, Goyne H, Stone PJ, Chiriva-Internati M. Dendritic cell vaccination against ovarian cancer--tipping the Treg/TH17 balance to therapeutic advantage? Expert Opin Biol Ther. 2011 Apr; 11(4):441-5. PMID: 21271951.
      View in: PubMed
    27. Cannon, M.J, Goyne, H, Stone, P.J.B, Chiriva-Internati, M. Dendritic cell vaccination agains ovarian cancer-tipping the Treg/Th17 balance to therapeutic advantage?. Exp. Opin. Biol. Therapy. 2011; (In Press).
    28. Chiriva-Internati, M, Mirandola, L, Jenkins, M. R, Cannon, M.J, Cobos, E, Kast, W. M. Clinical perspectives in cancer vaccines for hematogical diseases. Cancer Vaccines, 2nd Edition (F. Marincola, Ed.) Informa Healhcare, London. 2011.
    29. Chiriva-Internati M, Yu Y, Mirandola L, Jenkins MR, Chapman C, Cannon M, Cobos E, Kast WM. Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer. PLoS One. 2010 May 12; 5(5):e10471. PMID: 20485677.
      View in: PubMed
    30. Chiriva-Internati M, Yu Y, Jenkins RM, Cannon M, Chapman C, Cobos E, Kast WM. Sperm protein 17 vaccination induces a long-term protective immune response against ovarian cancer. 24th Annual meeting of the International Society for Biological Therapy of Cancer. 2010.
    31. Chiriva-Internati M, Yu Y, Jenkins M, Cannon M, Chapman C, Cobos E, Kast WM. Effective prevention and therapy of ovarian cancer with sperm protein 17 vaccination. 97th Annual meeting of the American Association of Immunologists. 2010.
    32. Cannon M, O'Brien TJ, Chiriva-Internati M. Dendritic cell redirection of regulatory T cell responses to ovarian cancer antigens. 24th Annual meeting of the International Society for Biological Therapy of Cancer. 2010.
    33. Cannon MJ, O'Brien TJ. Cellular immunotherapy for ovarian cancer. Expert Opin Biol Ther. 2009 Jun; 9(6):677-88. PMID: 19456205.
      View in: PubMed
    34. Bellone S, Anfossi S, O'Brien TJ, Cannon MJ, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer. Cancer. 2009 Feb 15; 115(4):800-11. PMID: 19117353.
      View in: PubMed
    35. Cannon M, Rose DL, Kozak KL, O'Brien TJ, Cobos E, Chiriva-Internati M. Dendritic cells treated with IL-15 and a p38 MAP kinase inhibitor antagonize regulatory T cell activation and expansion and drive CD4+ Th17 responses to ovarian tumor antigens. In preparation. 2009.
    36. Chiriva-Internati M, Mirandola L, Yu Y, Cannon M, Chapman C, Chiaramonte R, Jenkins MR, Grizzi F, Cobos E, Kast WM. Cancer testis antigen Sperm autoantigenic protein 17 as a new target for breast cancer immunotherapy. In preparation. 2009.
    37. Kozak KL, Bondurant KL, O'Brien TJ, Cannon M. IL-15 and IL-1B independently diminish regulatory T cell activation and promote Th17 responses following stimulation by ovarian tumor-antigen-loaded dendritic cells. In preparation. 2009.
    38. Bondurant KL, Kozak KL, O'Brien TJ, Cannon M. CD4+ T cells recognition of multi-epitope regions within tumor-associated serine proteases. In preparation. 2009.
    39. Bellone S, Anfossi S, O'Brien TJ, Cannon M, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Generation of CA125-specific cytotoxic T lymphocytes in human leukocyte antigen A2-positive healthy donors and patients with advanced ovarian cancer. Am. J. Obstet. Gynecol. 2009; 200:75e1-10.
    40. Yu Y, Pilgrim P, Zhou W, Gagliano N, Frezza EE, Jenkins M, Weidanz JA, Lustgarten J, Cannon M, Bumm K, Cobos E, Kast WM, Chiriva-Internati M. rAAV/Her-2/neu loading of dendritic cells for a potent cellular-mediated MHC class I restricted immune response against ovarian cancer. Viral Immunol. 2008 Dec; 21(4):435-42. PMID: 19115932.
      View in: PubMed
    41. Bellone S, Anfossi S, O'Brien TJ, Cannon MJ, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Generation of CA125-specific cytotoxic T lymphocytes in human leukocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer. Am J Obstet Gynecol. 2009 Jan; 200(1):75.e1-10. PMID: 18976739.
      View in: PubMed
    42. Yu Y, Pilgrim P, Yan J, Zhou W, Jenkins M, Gagliano N, Bumm K, Cannon M, Milzani A, Dalle-Donne I, Kast WM, Cobos E, Chiriva-Internati M. Protective CD8+ T-cell responses to cytomegalovirus driven by rAAV/GFP/IE1 loading of dendritic cells. J Transl Med. 2008 Oct 05; 6:56. PMID: 18834548.
      View in: PubMed
    43. Santin AD, Bellone S, Palmieri M, Zanolini A, Ravaggi A, Siegel ER, Roman JJ, Burnett AF, Pecorelli S, Cannon M. Human papillomavirus 16/18 E7-pulsed dendritic cell vaccination in stage IB-IIA cervical cancer patients: A phase I escalating dose trial. J. Virol. 2008; 82:1968-1979.
    44. Santin AD, Bellone S, Palmieri M, Zanolini A, Ravaggi A, Siegel ER, Roman JJ, Pecorelli S, Cannon MJ. Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial. J Virol. 2008 Feb; 82(4):1968-79. PMID: 18057249.
      View in: PubMed
    45. Bellone S, Pecorelli S, Cannon MJ, Santin AD. Advances in dendritic-cell-based therapeutic vaccines for cervical cancer. Expert Rev Anticancer Ther. 2007 Oct; 7(10):1473-86. PMID: 17944571.
      View in: PubMed
    46. Pashov A, Monzavi-Karbassi B, Chow M, Cannon M, Kieber-Emmons T. Immune surveillance as a rationale for immunotherapy? Hum Vaccin. 2007 Sep-Oct; 3(5):224-8. PMID: 17660717.
      View in: PubMed
    47. SANTIN AD, BELLONE S, PALMIERI M, ZANOLINI A, RAVAGGI A, SIEGEL ER, ROMAN JJ, BURNETT AF, PECORELLI S, Cannon M. HUMAN PAPILLOMAVIRUS 16/18 E7-PULSED DENDRITIC CELL VACCINATION IN STAGE IB-IIA CERVICAL CANCER PATIENTS: A PHASE I ESCALATING DOSE TRIAL. 2007.
    48. BELLONE S, PECORELLI S, Cannon M, SANTIN AD. ADVANCES IN DENDRITIC CELL-BASED THERAPEUTIC VACCINES FOR CERVICAL CANCER. EXP. REV. ANTICANCER THERAPHY. 2007; PP 1473-1486.
    49. BONDURANT KL, TENG Y, KOZAK KL, OBRIEN TJ, Cannon M. T CELL RECOGNITION OF MULTI-EPITOPE REGIONS WITHIN THE OVARIAN TUMOR ANTIGENS MATRIPTASE AND STRATUM CORNEUM CHYMOTRYPTIC ENZYME. SUBMITTED, J. IMMUNOTHERAPY. 2007.
    50. KOZAK KL, BONDURANT KL, OBRIEN TJ, Cannon M. INTERLEUKIN 15 DIMINISHES REGULATORY T CELL ACTIVATION BY CYTOKINE-MATURED DENDRITIC CELLS. SUBMITTED, CLIN. CANCER RESEARCH. 2007.
    51. Cannon M. IMMUNOTERAPIA RAKA JAJNIKA OPARTA NA KOMORKACH DENDRYTYCZNYCH. IMMUNOTERAPIA W GINEKOLOGII I POLOZNICTWIE (EDS. KOTARSKI & BEWDNAREK). 2007; PP165-174.
    52. Cannon, M.J. Immunoterapia raka jajnika oparta na komorkach dendrytycznych. Immunoterpia w ginekologii i poloznictwie. (J Kotarski & W. Bewdnarek, Eds.). BiolFolium, Lublin. 2007; 165-174.
    53. KOZAK KL, BONDURANT KL, OBRIEN TJ, Cannon M. IL-15 POTENTIATION OF EFFECTOR CD4+AND CD8+ T CELL RESPONSES INDUCED BY MATRIPTASE PEPTIDE-LOADED DENDRITIC CELLS. MOLECULAR TARGETS IN CANCER THERAPY. 2007.
    54. Kim KH, Dishongh R, Santin AD, Cannon MJ, Bellone S, Nakagawa M. Recognition of a cervical cancer derived tumor cell line by a human papillomavirus type 16 E6 52-61-specific CD8 T cell clone. Cancer Immun. 2006 Jun 30; 6:9. PMID: 16808432.
      View in: PubMed
    55. SANTIN AD, BELLONE S, PALMIERI M, RAVAGGI A, ROMANI C, TASSI R, ROMAN JJ, BURNETT A, PECORELLI S, Cannon M. HPV16/18 E7-PULSED DENDRITIC CELL VACCINATION IN CERVICAL CANCER PATIENTS WITH RECURRENT DISEASE REFRACTORY TO STANDARD TREATMENT MODALITIES.GYNECOL.ONCOL. 2006; 100:469-478.
    56. Kim KH, Dishongh R, Santin AD, Cannon M, Bellone S, Nakagawa M. The recognition of a cervical cancer derived tumor cell line by a human papillomavirus type 16 E6 52-61 specific CD8 T cell clone. Cancer Immunity. 2006; 66:9.
    57. Santin AD, Bellone S, Palmieri M, Ravaggi A, Romani C, Tassi R, Roman JJ, Burnett A, Pecorelli S, Cannon MJ. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. Gynecol Oncol. 2006 Mar; 100(3):469-78. PMID: 16249018.
      View in: PubMed
    58. Bellone S, Watts K, Cane' S, Palmieri M, Cannon MJ, Burnett A, Roman JJ, Pecorelli S, Santin AD. High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer. Gynecol Oncol. 2005 Jul; 98(1):92-8. PMID: 15904949.
      View in: PubMed
    59. Li S, Zhang L, Torrero M, Cannon M, Barret R. Administration route- and immune cell activation-dependent tumor eradication by IL12 electrotransfer. Mol Ther. 2005 Nov; 12(5):942-9. PMID: 15953768.
      View in: PubMed
    60. Santin AD, Can? S, Bellone S, Palmieri M, Siegel ER, Thomas M, Roman JJ, Burnett A, Cannon MJ, Pecorelli S. Treatment of chemotherapy-resistant human ovarian cancer xenografts in C.B-17/SCID mice by intraperitoneal administration of Clostridium perfringens enterotoxin. Cancer Res. 2005 May 15; 65(10):4334-42. PMID: 15899825.
      View in: PubMed
    61. Bondurant KL, Crew MD, Santin AD, O'Brien TJ, Cannon MJ. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme. Clin Cancer Res. 2005 May 01; 11(9):3446-54. PMID: 15867247.
      View in: PubMed
    62. Wahid R, Cannon MJ, Chow M. Virus-specific CD4+ and CD8+ cytotoxic T-cell responses and long-term T-cell memory in individuals vaccinated against polio. J Virol. 2005 May; 79(10):5988-95. PMID: 15857985.
      View in: PubMed
    63. Santin AD, Bellone S, Siegel ER, Palmieri M, Thomas M, Cannon MJ, Kay HH, Roman JJ, Burnett A, Pecorelli S. Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer. Am J Obstet Gynecol. 2005 Mar; 192(3):813-8. PMID: 15746676.
      View in: PubMed
    64. Rochford R, Cannon MJ, Moormann AM. Endemic Burkitt's lymphoma: a polymicrobial disease? Nat Rev Microbiol. 2005 02; 3(2):182-7. PMID: 15685227.
      View in: PubMed
    65. Santin AD, Zhan F, Bignotti E, Siegel ER, Can? S, Bellone S, Palmieri M, Anfossi S, Thomas M, Burnett A, Kay HH, Roman JJ, O'Brien TJ, Tian E, Cannon MJ, Shaughnessy J, Pecorelli S. Gene expression profiles of primary HPV16- and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy. Virology. 2005 Jan 20; 331(2):269-91. PMID: 15629771.
      View in: PubMed
    66. Crew MD, Cannon MJ, Phanavanh B, Garcia-Borges CN. An HLA-E single chain trimer inhibits human NK cell reactivity towards porcine cells. Mol Immunol. 2005 Jun; 42(10):1205-14. PMID: 15829309.
      View in: PubMed
    67. Wahid R, Cannon MJ, Chow M. Dendritic cells and macrophages are productively infected by poliovirus. J Virol. 2005 Jan; 79(1):401-9. PMID: 15596833.
      View in: PubMed
    68. Santin AD, Bellone S, Roman JJ, Burnett A, Cannon MJ, Pecorelli S. Therapeutic vaccines for cervical cancer: dendritic cell-based immunotherapy. Curr Pharm Des. 2005; 11(27):3485-500. PMID: 16248803.
      View in: PubMed
    69. Bellone S, Watts K, Cane S, Palmieri M, Cannon M, Burnett A, Roman JJ, Pecorelli S, Santin AD. High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology;a highly aggressive and chemotheraphy resistant variant of endometrial cancer. Gynecol. Oncol. 2005; 98:92-98.
    70. Bondurant KL, Crew MD, Santin AD, O'Brien TJ, Cannon M. Definition of an immunodominant region within the ovarian tumor antigen stratum corneum chymotryptic enzyme. Clin. Cancer Res. 2005; 11:3446-3454.
    71. Santin AD, Zhan F, Cane S, Bellone S, Palmieri M, Thomas M, Burnett A, Roman JJ, Cannon M, Shaughnessy Jr J, Pecorelli S. Gene expression fingerprint of uterine serous papillary carcinoma: Identification of novel molecular makers for uterine serous cancer diagnosis and therapy. Brit. J. Cancer. 2005; 92:1561-1573.
    72. Santin AD, Cane S, Bellone S, Palmieri M, Siegel ER, Thomas M, Roman JJ, Burnett A, Cannon M, Pecorelli S. Treatment of chemotheraphy-resistant human ovarian cancer xenografts in C.B-17/SCID mice by intraperitoneal administration of Clostridium perfringens enterotoxin (CPE). Cancer Res. 2005; 65:4664-4342.
    73. Santin AD, Bellone S, Siegel ER, Palmieri M, Thomas M, Burnett A, Kay HH, Roamn JJ, Cannon M, Pecorelli S. Racial differences in overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer. Am. J. Obstet. Gynecol. 2005; 192:813-818.
    74. Santin AD, Bellone S, Roman JJ, Burnett A, Cannon M, Pecorelli S. Therapeutic vaccines for cervical cancer: Dendritic-based immunotheraphy. Current Pharm. Design. 2005; 11:3485-3500.
    75. Santin AD, Zhan F, Bellone S, Palmieri M, Cane S, Bignotti E, Anfossi S, Gokden M, Dunn D, Roman JJ, O'Brien TJ, Tian E, Cannon MJ, Shaughnessy J, Pecorelli S. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int J Cancer. 2004 Oct 20; 112(1):14-25. PMID: 15305371.
      View in: PubMed
    76. Santin AD, Bellone S, O'Brien TJ, Pecorelli S, Cannon MJ, Roman JJ. Current treatment options for endometrial cancer. Expert Rev Anticancer Ther. 2004 Aug; 4(4):679-89. PMID: 15270671.
      View in: PubMed
    77. Santin AD, Ravindranath MH, Bellone S, Muthugounder S, Palmieri M, O'Brien TJ, Roman J, Cannon MJ, Pecorelli S. Increased levels of gangliosides in the plasma and ascitic fluid of patients with advanced ovarian cancer. BJOG. 2004 Jun; 111(6):613-8. PMID: 15198791.
      View in: PubMed
    78. Cannon MJ, Santin AD, O'Brien TJ. Immunological treatment of ovarian cancer. Curr Opin Obstet Gynecol. 2004 Feb; 16(1):87-92. PMID: 15128013.
      View in: PubMed
    79. Can? S, Bignotti E, Bellone S, Palmieri M, De las Casas L, Roman JJ, Pecorelli S, Cannon MJ, O'brien T, Santin AD. The novel serine protease tumor-associated differentially expressed gene-14 (KLK8/Neuropsin/Ovasin) is highly overexpressed in cervical cancer. Am J Obstet Gynecol. 2004 Jan; 190(1):60-6. PMID: 14749636.
      View in: PubMed
    80. Santin AD, Zhan F, Bellone S, Palmieri M, Cane S, Gokden M, Roman JJ, O'Brien TJ, Tian E, Cannon M, Shaughnessy Jr. J, Pecorelli S. Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumors by gene expression profiling. Brit. J. Cancer. 2004; 90:1814-1824.
    81. Santin AD, Zhan F, Bellone S, Palmieri M, Cane S, Bignotti E, Anfossi S, Gokden M, Dunn D, Roman JJ, O'Brien TJ, Tian E, Cannon M, Shaughnessy Jr J, Pecorelli S. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: Identification of candidate molecular markers for ovarian cancer diagnosis and theraphy. Int. J. Cancer. 2004; 112:14-25.
    82. Bellone S, Palmieri M, Gokden M, Joshua J, Roman JJ, Pecorelli S, Cannon MJ, Santin AD. Selection of HER-2/neu-positive tumor cells in early stage cervical cancer: implications for Herceptin-mediated therapy. Gynecol Oncol. 2003 Oct; 91(1):231-40. PMID: 14529687.
      View in: PubMed
    83. Kass R, Bellone S, Palmieri M, Can? S, Bignotti E, Henry-Tillman R, Hutchins L, Cannon MJ, Klimberg S, Santin AD. Restoration of tumor-specific HLA class I restricted cytotoxicity in tumor infiltrating lymphocytes of advanced breast cancer patients by in vitro stimulation with tumor antigen-pulsed autologous dendritic cells. Breast Cancer Res Treat. 2003 Aug; 80(3):275-85. PMID: 14503800.
      View in: PubMed
    84. Kass R, Agha J, Bellone S, Palmieri M, Can? S, Bignotti E, Henry-Tillman R, Hutchins L, Cannon MJ, Klimberg S, Santin AD. In vitro induction of tumor-specific HLA class I-restricted CD8+ cytotoxic T lymphocytes from patients with locally advanced breast cancer by tumor antigen-pulsed autologous dendritic cells. J Surg Res. 2003 Jun 15; 112(2):189-97. PMID: 12888337.
      View in: PubMed
    85. Santin AD, Bellone S, Palmieri M, Bossini B, Roman JJ, Cannon MJ, Bignotti E, Can? S, Pecorelli S. Induction of tumor-specific cytotoxicity in tumor infiltrating lymphocytes by HPV16 and HPV18 E7-pulsed autologous dendritic cells in patients with cancer of the uterine cervix. Gynecol Oncol. 2003 May; 89(2):271-80. PMID: 12713991.
      View in: PubMed
    86. Khanolkar A, Fu Z, Underwood LJ, Bondurant KL, Rochford R, Cannon MJ. CD4+ T cell-induced differentiation of EBV-transformed lymphoblastoid cells is associated with diminished recognition by EBV-specific CD8+ cytotoxic T cells. J Immunol. 2003 Mar 15; 170(6):3187-94. PMID: 12626577.
      View in: PubMed
    87. Kass R, Agha J, Bellone S, Palmieri M, Cane S, Bignotti E, Henry-Tillman R, Hutchins L, Cannon M, Klimberg S, Santin AD. In vitro induction of tumor-specific HLA class I restricted CD8+ cytotoxic T lymphocytes from patients with locally advanced breast cancer by tumor antigen oulsed autologous dendritic cells. J. Surgical Res. 2003; 112:189-197.
    88. Santin AD, Bellone S, Parrish RS, Coke C, Dunn D, Roman J, Theus JW, Cannon M, Parham GP, Pecorelli S. Influence of allogenic blood transfusion on clinical outcome during radiotherapy for cancer of the uterine cervix. Gynecol. Obstet. Invest. 2003; 56:28-34.
    89. Santin AD, Bellone S, Palmieri M, Bossini B, Dunn D, Roman JJ, Pecorelli S, Cannon M, Parham GP. Effect of blood transfusion during radiotherapy on the immune function of patients with cancer of the uterine cervix: role of interleukin-10. Int J Radiat Oncol Biol Phys. 2002 Dec 01; 54(5):1345-55. PMID: 12459356.
      View in: PubMed
    90. Santin AD, Bellone S, Gokden M, Cannon MJ, Parham GP. Vaccination with HPV-18 E7-pulsed dendritic cells in a patient with metastatic cervical cancer. N Engl J Med. 2002 May 30; 346(22):1752-3. PMID: 12037163.
      View in: PubMed
    91. Santin AD, Bellone S, Gokden M, Palmieri M, Dunn D, Agha J, Roman JJ, Hutchins L, Pecorelli S, O'Brien T, Cannon MJ, Parham GP. Overexpression of HER-2/neu in uterine serous papillary cancer. Clin Cancer Res. 2002 May; 8(5):1271-9. PMID: 12006548.
      View in: PubMed
    92. Cannon MJ, O'Brien TJ, Underwood LJ, Crew MD, Bondurant KL, Santin AD. Novel target antigens for dendritic cell-based immunotherapy against ovarian cancer. Expert Rev Anticancer Ther. 2002 Feb; 2(1):97-105. PMID: 12113075.
      View in: PubMed
    93. Santin AD, Bellone S, Palmieri M, Bossini B, Dunn D, Roman J, Pecorelli S, Cannon M, Parham GP. Effect of allogeneic blood transfusion during radiotherapy on the immune function of patients with cancer of the uterine cervix:role of interleukin-10. Int. J. Radiation Oncol. 2002; 54:1345-1355.
    94. Santin AD, Hermonat PL, Ravaggi A, Bellone S, Pecorelli S, Parham GP, Cannon M. Induction of tumor-specific CD8+ cytotoxic T lymphocytes by tumor lysate-pulsed autologous dendritic cells in patients with serous papillary uterine cancer. Brit. J. Cancer. 2002; 86:151-157.
    95. Santin AD, Bellone S, Gokden M, Palmieri M, DunnD, Agha J, Roman JJ, Hutchins L, Pecorelli S, O'Brien TJ, Cannon M, Parham GP. Overexpression of HER-2/neu in uterus serous papillary cancer. Clin. Cancer Res. 2002; 8:1271-1279.
    96. Santin AD, Bellone S, Gokden M, Cannon M, Parham GP. HPV18 E7-pulsed dendritic cell vaccination in a patient with metastatic cervical cancer. New Engl. J. Med. 2002; 346:1752-1753.
    97. Cannon M, O'Brien TJ, Underwood LJ, Crew MD, Bondurant KL, Santin AD. Novel target antigens for dendritic cell immunotheraphy of ovarian cancer. Exp. Rev. Anticancer Theraphy. 2002; 22:89-97.
    98. Santin AD, Bellone S, Underwood LJ, O'Brien TJ, Ravaggi A, Pecorelli S, Cannon M. Novel immunotherapeutic strategies in gynecologic oncology. Dendritic cell-based immunotheraphy for ovarian cancer. Minerva Ginecologica. 2002; 54:133-144.
    99. Chiriva-Internati M, Du J, Cannon M, Barlogie B, Yi Q. Myeloma-reactive allospecific cytotoxic t lymphocytes lyse target cells by the granule exocytosis pathway. Brit. J. Haematol. 2001; 112:410-420.
    100. Clemons-Miller AR, Chatta GS, Hutchins L, Angtuaco EJ, Ravaggi A, Santin AD, Cannon M. Intrathecal cytotoxic T cell immunotherapy for metastic leptomeningeal melanoma. Clin. Cancer Res. 2001; 7(917s-924s).
    101. Santin AD, Bellone S, Ravaggi A, Roman J, Smith CV, Pecorelli S, Cannon M, Parham GP. Increased levels of interleukin-10 and transforming growth factor-B in the plasmam and ascitic fluid of patients with advanced ovarian cancer. Brit. J. Obstet. Gynecol. 2001; 108:804-808.
    102. Santin AD, Hermonat PL, Ravaggi A, Bellone S, Roman J, Pecorelli S, Cannon M, Parham GP. Effects of concurrent cisplatinum administration during radiotherapy versus radiotherapy alone on the immune function of patients with cancer of the uterine cervix. Int. J. Radiation Oncol. 2000; 48:997-1006.
    103. Santin AD, Hermonat PL, Ravaggi A, Pecorelli S, Cannon M, Parham GP. Induction of tumor-specific HLA class I-restricted CD8+ cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells in patients with advanced ovarian cancer. Am. J. Obstet. Gynecol. 2000; 183:601-609.
    104. Santin AD, Bellone S, Ravaggi A, Pecorelli S, Cannon M, Parham GP. Induction of ovarian tumor-specified CD8+ cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells. Obstetrics and Gynecology. 2000; 96:422-430.
    105. Santin AD, Hermonat PL, Ravaggi A, Bellone S, Pecorelli S, Roman JJ, Parham GP, Cannon M. Interleujin-10 increases Th1 cytokine production and cytotoxic potential in human papillomavirus-specific CD8+ cytotoxic T lymphocytes. J Virol. 2000; 74:4729-4737.
    106. Cannon M, Osborn CK, Nazaruk RA, Grigoriev V, Crew MD. Dimished recognition of HLA-A2 proteins lacking a cytoplasmic domain (CY) by A2-restricted, EBV-specific CTLs: Possible role of the CY in TAP association,. Immunogenetics. 1999; 49:346-350.
    107. Santin AD, Hermonat PL, Ravaggi A, Chiriva-Internati M, Pecorelli S, Cannon M, Parahm GP. Secretion of vascular endothelial growth factor (VEGF) in adenocarcinoma and squamous cell carcinoma of the uterine cervix. Obstetrics and Gynecology. 1999; 94:78-82.
    108. Santin AD, Hermonat PL, Ravaggi A, Chiriva-Internati M, Zhan DJ, Pecorelli S, Parham GP, Cannon M. Induction of human papillomavirus-specific CD4+ and CD8+ T cell responses by E7 pulsed autologous dendritic cells in patients with HPV16 and HPV18-positive cervical cancer. J Virol. 1999; 73:5402-5410.
    109. Nazaruk RA, Rochford R, Hobbs MV, Cannon M. Functional diversity of the CD8+ T cell response to Epstein-Barr virus: Implications for the pathogenesis of EBV-associated lymphoproliferative disorders. Blood. 1998; 91:3875-3883.
    110. Cannon M, Reed LD, Mawulawde K. Evidence for a Type 2 basis in the CD8+ T cell response to Epstein-Barr virus following heart transplantation. Transplant Proc. 1998; 30:1136-1139.
    111. Garnier JL, Cooper NR, Cannon M. Low expression of CD20 and CD23 in Epstein-Barr virus-induced tumors in SCID/hu mice. Am. J. Pathol. 1993; 142:353-358.
    112. Cooper NR, Rochford R, Garnier JL, Cirone M, Hobbs MV, Cannon M. The SCID/hu model of EBV-induced human B cell lymphoproliferative disease: Insights for diagnosis, prevention, and treatment. Proceedings of the Vth International Symposium on Epstein-Barr virus and Related Diseases, Colloques INSERM. 1993; 225:541-548.
    113. Pisa P, Cannon M, Pisa EK, Cooper NR, Fox RI. Epstein-Barr virus-induced lymphoproliferative tumors in SCID mice are oligoclonal. Blood. 1992; 79:173-179.
    114. Garnier JL, Pisa P, Cirone M, Rochford R, Fox RI, Cannon M, Cooper NR. Epstein-Barr virus-induced lymphoproliferative disorders in SCID/hu chimeric mice. Transplantation and Clinical Immunology (J.L. Touraine, J. Traeger, H. Beutel, J.M. Dubernard, J.P. Revillard and C. Dupuy, Eds.). 1991; 237-245.
    115. Cannon M, Openshaw PJM, Askonas BA. Lethal pulmonary disease in respiratory syncytial virus-infected mice following transfer to cytotoxic T cells. Vaccines '89: Modern Approaches to New Vaccines Including Prevention of AIDS. 1989; 497-499.
    116. Askonas BA, Openshaw PJM, Cannon M. T cells in respiratory syncytial virus (RSV) infection. Adv. Exp. Med. Biol. 1989; 257:9-17.
    117. Cannon M, Russell PH. Specificity of chicken secondary in vitro lymphoproliferative responses to a parakeet isolate of avian paramyxovirus-3. Avian Pathol. 1988; 170:508-510.
    118. Pemberton RM, Cannon M, Openshaw PJM, Ball LA, Wertz GW, Askonas BA. Cytotoxic T-cell specificity for respiratory syncytial virus: Fusion protein is an important target antigen. J. Gen. Virol. 1987; 68:2177-2182.
    119. Cannon M, Stott EJ, Taylor G, Askonas BA. Clearance of persistent respiratory sybcytial virus infections in immunodeficient mice following transfer to primed T cells. Immunology. 1987; 62:133-138.
    120. Cannon M. Microplaque immunoperoxidase detection of infectious respiratory syncytial virus in the lungs of persistently infected mice. J Virol Meth. 1987; 16:293-301.
    121. Russell P.H., Griffiths P.C., Cannon M. A microwell immunoperoxidase test for screening hybridomas and for diagnosing Newcastle disease virus and Sendai virus. J. Immunol Meth. 1983; 61:165-170.
    122. Russell P.H., Griffiths P.C., Goswami K.K.A., Alexander D.J., Cannon M, Russell W.C. The characterization of monoclonal antibodies to Newcastle disease virus. J Gen Virol. 1983; 64:2069-2072.
    123. Santin AD, Hermonat PL, Ravaggi A, Bellone S, Pecorelli S, Cannon M, Parham GP. Induction of tumor-specific CD8+ cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells in patients with advanced ovarian cancer. Society of Gynecologic Oncologists 31st Annual Meeting.
    124. BONDURANT KL, WAHID R, OBRIEN TJ, Cannon M. MULTI-EPITOPE PEPTIDE-LOADED DENDRITIC CELLS INDUCE CD4+ AND CD8+EFFECTOR T CELL RESPONSES COUNTERBALANCED BY REGULATORY T CELL FUNCTION. MOLECULAR TARGETS IN CANCER THERAPY.
    125. Santin AD, Hermonat PL, Ravaggi A, Chiriva-Internati M, Zhan DJ, Pecorelli S, Cannon M, Parham GP. Induction of human papillomavirus-specific CD4+ and CD8+ T cell responses by E7 pulsed autologous dendritic cells in patients with HPV16 and HPV18-positive cervical cancer. 90th Annual Meeting of the American Association for Cancer Research.
    126. Khanolkar A, Fu Z, Rochford R, Cannon M. CD4+ T cell-induced differentiation of EBV-transformed lymphoblastoid cells results in diminished recognition by EBV-specific CD8+ cytotoxic t cells. American Society for Microbiology, South-Central meeting.
    127. Santin AD, Bellone S, Palmieri M, Gokden M, Roman J, Pecorelli S, Cannon M, Parham GP. HER2/neu overexpression in uterine serous papillary carcinoma. Society of Gynecologic Oncologists 33rd Annual Meeting.
    128. Santin AD, Hermonat PL, Ravaggi A, Bellone S, Pecorelli S, Parham GP, Cannon M. Induction of tumor-specific CD8+ cytotoxic T lymphocytes by tumor lysate-pulsed autologous dendritic cells in patients with serous papillary uterine cancer. AACR 92nd Annual Meeting.
    129. Santin AD, Bellone S, Palmieri M, Cane S, Siegel ER, Thomas M, Roman JJ, Burnett A, Cannon M, Pecorelli S. Treatment of chemotherapy-resistant human ovarian cancer xenografts in C.B-17/SCID mice by intraperitoneal administration of Clostridium perfringens enterotoxin (CPE). Society of Gynecologic Oncologists.
    130. Clemons-Miller AR, Chatta GS, Hutchins L, Cannon M. Treatment of a patient with metastatic leptomeningeal melanoma by injection of autologous cytotoxic T cells. Keystone Symposium on Cellular Immunity and Immunotherapy of Cancer.
    131. Khanolkar A, Fu Z, Underwood LJ, Bondurant KL, Cannon M, Rochford R. CD4+ T cells induce plasmacytoid differentiation of Epstein-Barr virus-transformed lymphoblastoid cells. 10th International EBV Symposium.
    132. Santin AD, Hermonat PL, Ravaggi A, Chiriva-Internati M, Zhan DJ, Pecorelli S, Parham GP, Cannon M. Induction of specific cytotoxic T cells by dendritic cells primed with acid-eluted autologous peptides in patients with ovarian cancer. Society for Gynecologic Oncology.
    133. Kim KH, Santin AD, Cannon M, Bellone S, Nakagawa M. The HPV 16 E6 52-61 CD8 T cell epitope as a source of antigen for dendritic cell immunotherapy for cervical cancer. 22nd International Papollomavirus Conference and Clinical Workshop.
    134. Bondurant KL, O'Brien TJ, Santin AD, Crew MD, Cannon M. T cell responses to SCCE ovarian tumor antigen. 12th International Congress of Immunology.
    135. Khanolkar A, Yagita H, Cannon M. Mechanisms of target cell lysis employed by Epstein-Barr virus-specific CD4+ T cells. Immunology 2000 (joint AAI/CIS annual meeting).
    136. Cannon M, Reed LD, Mawulawde K. Evidence for a Type 2 basis in the CD8+ T cell response to Epstein-Barr virus following heart transplantation. International Congress on Immunosuppression.
    137. Crew MD, Osborn CK, Grigoriev V, Cannon M. Role of HLA class I transmembrane and cytoplasmic domains in antigen presentation. Keystone Symposium on Immunogenetics of Human Disease MHC/TCR and Peptide.
    138. Wahid R, Cannon M, Chow M. Poliovirus infection of dendritic cells. 6th International Symposium on Positive Strand RNA Viruses.
    139. KIM KH, DISHONGH R, SANTIN AD, Cannon M, BELLONE S. THE RECOGNITION OF A CERVICAL CANCER DERIVED TUMOR CELL LINE BY A HUMAN PAPILLOMAVIRUS TYPE 16 E6 52-61-SPECIFIC CD8 T CELL CLONE.
    140. Cannon M, Kozak KL, O'Brien TJ. Cellular immunotherapy and immune regulation in ovarian cancer. 23rd Annual meeting of the International Society for Biological Therapy of Cancer.
    141. Santin AD, Hermonat PL, Ravaggi A, Bellone S, Pecorelli S, Cannon M, Parham GP. Induction of tumor-specific CD8+ lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells in patients with advanced ovarian cancer. Keystone Symposium on Cellular Immunity and Immunotherapy of Cancer.
    142. Fu Z, Rochford R, Khanolkar A, Cannon M. T cell-mediated induction of the EBV lytic cycle in latently infected B cells. 23rd International Herpesvirus Workshop.
    143. Khanolkar A, Cannon M. Functional analysis of the CD4+ T cell response to Epstein-Barr virus. European Epstein-Barr virus meeting.
    144. Wahid R, Chow M, Cannon M. Poliovirus infection of hematopoietic cells. American Society for Virology Annual Meeting.
    145. Cannon M, Nazaruk RA, Hobbs MV, Rochford R. Expression of type 2 cytokines and activation of resting B cells by Epstein-Barr virus-specific CD8+ T cells. International Herpesvirus Workshop.
    146. Cannon M, BONDURANT, KL, OBRIEN TJ. DENDRITIC CELL IMMUNOTHERAPHY TARGETED AGAINST TUMOR ASSOCIATED SERINE PROTEASES. 34TH MEETING OF THE INTERNATIONAL SOCIETY FOR ONCODEVELOPMENTAL BIOLOGY AND MEDICINE.
    147. Santin AD, Bellone S, Palmieri M, Cane S, Roman JJ, Cannon M, Pecorelli S. HPV16/18 E7-pulsed dendritic cell vaccination in patients with recurrent cervical cancer refractory to standard salvage therapy. International Gynecological Cancer Society.
    Cannon's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (295) concept(s)
    _
    Co-Authors Expand Description
    See all (21) people
    _
    Similar People Expand Description
    See all (36) people
    _
    Same Department Expand Description
    Search Department